№ files_lp_4_process_3_133082
File format: docx
Character count: 3487
File size: 111 KB
Systems Refractory Solutions is a new business unit providing refractory maintenance services for steel mills, aiming to improve operational efficiency, safety, and equipment longevity.
Year:
2026
Region / City:
Little Rock, AR
Industry:
Steel manufacturing, refractory maintenance
Document Type:
Press release
Organization:
The Systems Group
Author:
Kyle Morgan (President)
Target Audience:
Steel industry professionals, media
Effective Date:
Immediate
Date of Release:
Not specified
Changes Date:
Not specified
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.
The file will be delivered to the email address provided at checkout within 12 hours.
Don’t have cryptocurrency yet?
You can still complete your purchase in a few minutes:- Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
- In the app, tap Send.
- Select network, paste our wallet address.
- Send the exact amount shown above.
The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Protocol version:
6.0
Date:
18 September 2020
Study name:
rEECur
Study design:
International randomised controlled trial
Medical condition:
Recurrent and primary refractory Ewing sarcoma
Intervention:
Chemotherapy
Sponsor:
University of Birmingham
Sponsor protocol number:
RG_13-277
CRCTU number:
SA2015
EudraCT number:
2014-000259-99
ISRCTN reference number:
ISRCTN36453794
Chief Investigator:
Dr Martin McCabe
Coordinating institution:
Cancer Research UK Clinical Trials Unit, University of Birmingham
Geographic scope:
International
Participating regions:
United Kingdom, Germany, Italy, France, Spain, Scandinavia, Australia, New Zealand, Switzerland
Target population:
Patients with recurrent or primary refractory Ewing sarcoma
Regulatory status:
Ethics and regulatory approval required per participating country
Amendment history:
Substantial amendments between 2014 and 2016
Document type:
Clinical trial protocol
Randomisation method:
Centralised online randomisation
Trial phase:
Phase II (Germany-specific limitation noted)
Year:
2024
Region / city:
United Kingdom
Topic:
Health technology assessment
Document type:
Appeal hearing report
Organization:
National Institute for Health and Care Excellence (NICE)
Author:
NICE
Target audience:
Healthcare professionals, industry representatives, public
Period of validity:
Not specified
Approval date:
23 September 2024
Date of changes:
Not specified
Year:
2021
Region / city:
London, UK
Theme:
Refractory Disease, Rheumatoid Arthritis, Juvenile Idiopathic Arthritis
Document type:
Systematic review
Organization / institution:
King’s College London
Authors:
Hema Chaplin, Lewis Carpenter, Anni Raz, Elena Nikiphorou, Heidi Lempp, Sam Norton
Target audience:
Medical professionals, researchers in rheumatology
Period of validity:
Not applicable
Date of approval:
Not stated
Date of amendments:
25.01.2021
Year:
2016
Region / city:
Australia
Topic:
Multiple myeloma treatment
Document type:
Submission for listing consideration
Organ / institution:
PBAC (Pharmaceutical Benefits Advisory Committee)
Author:
Takeda Pharmaceuticals Australia Pty Ltd
Target audience:
PBAC, healthcare professionals
Period of validity:
Ongoing treatment
Approval date:
15 November 2016
Date of changes:
N/A
Year:
2023
Region / City:
UK
Topic:
Medical / Health
Document Type:
Guidance
Institution:
National Institute for Health and Care Excellence (NICE)
Author:
Dr. Mark Chakravarty
Target Audience:
Pharmaceutical companies, healthcare professionals
Validity Period:
Not specified
Approval Date:
Not specified
Amendment Date:
Not specified
Year:
2024
Region / City:
Europe
Topic:
Waldenstrom’s Macroglobulinemia, Treatment Approaches
Document Type:
Clinical Trial Report
Author:
Meletios Dimopoulos, Maria Gavriatopoulou, Efstathios Kastritis, Christian Buske
Target Audience:
Medical Researchers, Oncologists, Hematologists
Study Phase:
Phase II
Date of Approval:
June 2024
Date of Changes:
N/A
Primary Endpoint:
Achievement of CR / VGPR at 12 and 24 months
Secondary Endpoints:
Time to best response, time to first response, time to treatment failure, remission duration, progression free survival, cause specific survival, overall survival, safety, quality of life
Year:
2019
Region / City:
United Kingdom
Topic:
Cancer, Hematology
Document Type:
Response to Consultation
Organization:
National Institute for Health and Care Excellence (NICE)
Author:
National Institute for Health and Care Excellence (NICE)
Target Audience:
Healthcare professionals, policy makers
Effective Period:
Not specified
Approval Date:
Not specified
Amendment Date:
June 2019
Year:
2026
Region / Institution:
Guangdong Ocean University, University of Science and Technology Beijing, AiMaterials Research LLC
Subject:
Materials science, machine learning, high-entropy alloys
Document type:
Supplementary data / research article
Authors:
Cheng Wen, Yan Zhang, Changxin Wang, Haiyou Huang, Yuan Wu, Turab Lookman, Yanjing Su
Corresponding authors:
Turab Lookman, Yanjing Su
Methodology:
Machine learning, NSGA-II algorithm, bootstrap sampling, Pareto optimization
Target properties:
Strength, ductility of refractory high-entropy alloys
Software / Tools:
RStudio, caret package
Data handling:
Training/testing data split, cross-validation, hyperparameter optimization
Publication context:
Supplementary material to a scientific study on alloy design
Year:
2017
Region / city:
United Kingdom
Subject:
Faecal microbiota transplant (FMT) for Clostridium difficile infection and other indications
Document type:
Clinical guidelines
Organization / institution:
British Society of Gastroenterology (BSG) and Healthcare Infection Society (HIS)
Authors:
Working group of BSG and HIS
Target audience:
Healthcare professionals, clinicians
Period of validity:
Ongoing (as of publication)
Approval date:
Not specified
Date of revisions:
Not specified
Scope:
Guidelines for the use of faecal microbiota transplant in treating Clostridium difficile infection (CDI) and other clinical conditions
Clinical management:
Recommendations for patient selection, donor selection, and FMT administration
Economic aspects:
Cost-effectiveness of FMT compared to traditional therapies for CDI
Year:
2026
Region / City:
Paschim Bardhaman, West Bengal, India
Product Type:
Fire Bricks, Mortars, Castable
Document Type:
Manufacturer Directory
Organization / Institution:
Local Industry Associations
Contact Information Included:
Yes
Production Capacity:
1200–2000 MT per month
Intended Audience:
Industrial buyers and suppliers
District:
Paschim Bardhaman
State:
West Bengal
Year:
2017
Country:
Australia
Program:
Pharmaceutical Benefits Scheme (PBS)
Section:
Section 100 Highly Specialised Drugs Program
Regulatory Authority:
Pharmaceutical Benefits Advisory Committee (PBAC)
Regulatory Agency:
Department of Human Services
Drug Name:
Pralatrexate
Brand Name:
Folotyn®
Manufacturer:
Mundipharma Pty Ltd
Dosage Form:
Solution for intravenous infusion, 20 mg in 1 mL
Maximum Quantity:
80 mg
Indication:
Relapsed or chemotherapy-refractory peripheral T-cell lymphoma
Target Population:
Adult patients with relapsed or refractory peripheral T-cell lymphoma after first-line chemotherapy
Treatment Regimen:
30 mg/m² intravenous infusion weekly for six weeks followed by one week rest
Treatment Phases:
Initial treatment; continuing treatment
Restriction Type:
Authority Required (Private and Public Hospital)
Clinical Criteria:
Relapsed or chemotherapy-refractory disease following front-line curative intent chemotherapy
Comparator Treatments:
DHAP, brentuximab, gemcitabine-containing regimens, methotrexate, romidepsin, ESHAP, ICE
Outcome Measures:
Overall survival, overall response rate, safety
Regulatory Status:
Registered by the Therapeutic Goods Administration (TGA) in December 2014
Therapeutic Area:
Oncology / Hematologic malignancies
Year:
2026
Region:
Kenya
Subject:
Refractory products and clay roofing tiles
Document Type:
Systematic Review Questionnaire
Organization:
Kenya Bureau of Standards
Responsible Person:
Eng. Lilian Kilatya
Dates of Circulation:
12th February 2026
Closing Date:
14th March 2026
Standards Included:
KS ISO 528:1983, KS ISO 5417:1986, KS ISO 836:2001, KS EAS 54:1999, KS EAS 71:2000, KS 431-1:2006 through KS 431-7:2006, KS 831-1:2001, KS 831-3:2001, KS 831-4:2001, KS 831-5:2001
Target Audience:
Potential users of Kenya Standards
Purpose:
To collect feedback on relevance and appropriateness of standards to market, regulatory, and technological needs
Year:
2026
Country:
Japan
Topic:
Cancer pain management
Document type:
Research article
Institution:
Juntendo University Graduate School of Medicine; National Cancer Center Hospital East; Saga-ken Medical Centre Koseikan; St. Marianna University School of Medicine; Tohoku University Graduate School of Medicine; Seirei Mikatahara General Hospital
Authors:
Yuko Uehara, Yoshihisa Matsumoto, Toshifumi Kosugi, Miyuki Sone, Naoki Nakamura, Akio Mizushima, Mitsunori Miyashita, Tatsuya Morita, Takuhiro Yamaguchi, Eriko Satomi
Target audience:
Palliative care physicians, interventional radiologists, oncologists, home hospice physicians
Study type:
Nationwide cross-sectional survey
Methods:
Self-administered questionnaire on four interventional procedures for cancer pain; descriptive and multivariate statistical analysis
Key procedures studied:
Celiac plexus neurolysis (CPN), phenol saddle block, epidural analgesia, intrathecal analgesia
Data collection period:
Past 3 years
Response rate:
545/1,112 PSs, 554/1,087 IVR specialists, 144/308 HHPs, 399/800 oncologists
Corresponding author:
Yoshihisa Matsumoto, National Cancer Center Hospital East, Kashiwa, Japan
Context:
Nationwide survey research article documenting the utilization, frequency, and factors influencing interventional procedures for refractory cancer pain among specialists and their familiarity among oncologists and home hospice physicians.
Year:
2020
Region / City:
Shanghai, China
Subject:
Medical Case Report
Document Type:
Case Report
Organization / Institution:
Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine
Author:
Ben Li, Guan-Wu Li, Luan Xue, Yue-Ying Chen
Target Audience:
Medical Professionals, Rheumatologists
Period of Action:
2020
Date of Approval:
August 29, 2020
Date of Revision:
June 18, 2020
Date of Publication:
October 06, 2020
Keywords:
Synovitis, acne, pustulosis, hyperostosis, osteitis syndrome, JAK inhibitor, tofacitinib, case report, rheumatoid arthritis, psoriatic arthritis
DOI:
https://dx.doi.org/10.12998/wjcc.v8.i19.4527
URL:
https://www.wjgnet.com/2307-8960/full/v8/i19/4527.htm
Context:
A medical case report describing the rapid response of a patient with SAPHO syndrome to the Janus kinase inhibitor tofacitinib after failure of conventional treatments.
Year:
2020
Region / City:
Hope Mills, North Carolina
Topic:
Financing Agreement, Local Government
Document Type:
Resolution
Government Body:
Board of Commissioners of the Town of Hope Mills
Author:
Board of Commissioners
Target Audience:
Local Government, Finance Authorities
Approval Date:
December 7, 2020
Amendment Date:
N/A
Year:
2026
Region / City:
Kentucky
Subject:
Legislation, Identity Documents
Document Type:
Bill
Organization / Institution:
Kentucky Senate
Author:
A. Reed, J. Higdon, G. Boswell, J. Carpenter, D. Carroll, M. Deneen, D. Douglas, G. Elkins, S. Funke Frommeyer, R. Girdler, D. Givens, S. Madon, A. Mays Bledsoe, S. Meredith, R. Mills, G. Neal, M. Nemes, M. Nunn, S. Rawlings, C. Richardson, B. Smith, R. Stivers, B. Storm, R. Webb, S. West, P. Wheeler, G. Williams, M. Wilson, M. Wise
Target Audience:
Kentucky residents
Period of Validity:
Effective July 1, 2027
Approval Date:
Jan 13, 2026
Amendment Date:
Jan 16, 2026
Year:
2014
Region / City:
Harare
Subject:
Legal dispute, machinery delivery, appeal process
Document type:
Court ruling
Organization / Institution:
Supreme Court of Zimbabwe
Author:
GUVAVA JA, MALABA DCJ, GOWORA JA
Target Audience:
Legal professionals, businesses involved in contracts
Period of validity:
Ongoing legal case
Date of approval:
January 31, 2014
Date of amendments:
None
Name:
Katherine T. Mills
Academic Degrees:
PhD in Epidemiology; MSPH in Epidemiology; BA in Chemistry
Current Position:
Associate Professor (with tenure)
Department:
Department of Epidemiology
Institution:
Tulane University School of Public Health and Tropical Medicine
Additional Appointment:
Adjunct Assistant Professor, Department of Neurology, Tulane University School of Medicine
Office Address:
Tidewater Building, Suite 2001, 1440 Canal Street, New Orleans, LA 70112
Email:
[email protected]
Phone:
(504) 988–4749
Mobile:
(423) 309-0126
Education:
Tulane University; University of North Carolina at Chapel Hill; Colorado College
Postdoctoral Training:
Johns Hopkins Bloomberg School of Public Health; Tulane University
Professional Experience:
Academic and research appointments in epidemiology, public health, and cardiovascular disease research
Research Areas:
Epidemiology; Cardiovascular Disease; Hypertension; Implementation Science; Health Disparities
Teaching Areas:
Epidemiologic Methods; Clinical Trials; Cardiovascular Disease Epidemiology; Implementation Science
Honors and Awards:
NIH and university research awards; Delta Omega Honorary Society inductee
Geographic Scope:
United States
Document Type:
Curriculum Vitae
Year:
2020
Region / City:
Portland, OR
Subject:
Precision Oncology, Cancer Research
Document Type:
Curriculum Vitae
Institution:
Oregon Health & Science University
Author:
Gordon B. Mills
Target Audience:
Academic and Medical Professionals
Period of Activity:
2018–present
Date of Approval:
April 18, 2020
Date of Last Modification:
April 18, 2020
Organization:
Kohinoor Textile Mills Limited (KTML)
Group:
Kohinoor Maple Leaf Group (KMLG)
Document Type:
Corporate Profile
Subject:
Board of Directors and Executive Management
Industry:
Textiles, Cement, Energy, Finance
Region:
Pakistan
Chairman:
Tariq Sayeed Saigol
Chief Executive Officer:
Taufique Sayeed Saigol
Independent Directors:
Shafiq Ahmed Khan; Zulfikar Monnoo
Group Director Finance / Chief Financial Officer:
Syed Mohsin Raza Naqvi
Associated Institutions Mentioned:
State Bank of Pakistan; All Pakistan Textile Mills Association; Lahore Chamber of Commerce and Industry; All Pakistan Cement Manufacturers Association; Lahore University of Management Sciences; Aitchison College, Lahore